- Joined
- Nov 16, 2015
- Messages
- 78
- Reaction score
- 4
This is a question i found on MTB step 2 ck, it said:
You have a patient with dilated cardiomyopathy secondary to MI in the past, that comes for routine evaluation, is asymptomatic, but with hyperkalemia. He is on lisinopril, furosemide, metoprolol, aspirin and digoxin.
What is the best management?
The answer was to change lisinopril (a IECA, so a possible cause of hyperKalemia) for hydralazine + nitroglycerin. This also lowers mortality, like IECAs, in CHF.
My question is... I remember from step 1 that hyperkalemia is dangerous and an important marker of acute toxicity with digoxin, and mortality predictor. So... shouldn't we take that into consideration too and maybe switch digoxin too or evaluate its levels?
Or maybe as the question says that the patient is ASYMPTOMATIC (not showing nausea, vomiting, diarrhea, xantopsia), we should not think of digoxin intoxication and switch the IECA for something else as it may cause hyperkalemia too??
You have a patient with dilated cardiomyopathy secondary to MI in the past, that comes for routine evaluation, is asymptomatic, but with hyperkalemia. He is on lisinopril, furosemide, metoprolol, aspirin and digoxin.
What is the best management?
The answer was to change lisinopril (a IECA, so a possible cause of hyperKalemia) for hydralazine + nitroglycerin. This also lowers mortality, like IECAs, in CHF.
My question is... I remember from step 1 that hyperkalemia is dangerous and an important marker of acute toxicity with digoxin, and mortality predictor. So... shouldn't we take that into consideration too and maybe switch digoxin too or evaluate its levels?
Or maybe as the question says that the patient is ASYMPTOMATIC (not showing nausea, vomiting, diarrhea, xantopsia), we should not think of digoxin intoxication and switch the IECA for something else as it may cause hyperkalemia too??